Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 206

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 206
---
 of, and the costs involved in, obtaining regulatory approvals for our product candidates; |

| • |     | the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates; |

| • |     | the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current 
 or future collaboration or license agreements;                                                                    |

| • |     | our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements                                                   
 and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; |

| • |     | the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, 
 is adopted by the physician community;                                                                            |

| • |     | our need to expand our research and development activities; |

| • |     | the costs of acquiring, licensing or investing in businesses, product candidates and technologies; |

| • |     | the effect of competing products and product candidates and other market developments; |

| • |     | the number and types of future products we develop and commercialize; |

| • |     | any product liability or other lawsuits related to our products; |

| • |     | the expenses needed to attract, hire and retain skilled personnel; |

| • |     | the costs associated with being a public company; |

129

| • |     | our need to implement additional internal systems and infrastructure, including financial and reporting systems; |

| • |     | the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending 
 intellectual property-related claims;                                                                       |

| • |     | the costs related to servicing of our debt; and |

| • |     | the extent and scope of our general and administrative expenses. |

Should our sales of ZTlido, GLOPERBA, ELYXYB and other product candidates not materialize at the anticipated rate contemplated in our business plan, we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise additional funds through various potential sources, such as equity and debt financings and license agreements. In addition to the liquidity provided by revenue generating products and the issuance of the Common Stock under the ATM